Navigation Links
TGen drug development teams with Oncoholdings to fight cancer

SCOTTSDALE, Ariz. Jan. 7, 2010 TGen Drug Development (TD2) and Oncoholdings Inc. announced today a partnership agreement that could lead to the prompt development of new anti-cancer agents.

Oncoholdings Inc. is a Syracuse, N.Y.-based pharmaceutical company focused on acquiring and developing the most promising preclinical and early clinical anti-cancer agents. It was founded by some of the world's leading oncology scientists and leverages the unique insights and experiences of its founders and world-class scientific advisory board.

TD2, based in Scottsdale, Ariz., provides drug development firms with expertise in moving promising laboratory discoveries through the pre-clinical, clinical and regulatory approval steps of getting new drugs to patients as quickly and safely as possible.

Under the agreement announced today, TD2 a subsidiary of the Phoenix-based Translational Genomics Research Institute (TGen) will be the exclusive development partner for Oncoholdings' oncology portfolio. The company plans to develop as many as 15 early-stage drugs over the next three years.

"We are extremely eager to put the scientific assets of Oncoholdings on the most expeditious and precise path, moving their drug compounds safely and effectively to benefit cancer patients who so desperately need better treatments," said Dr. Stephen Gately, President of TD2 and a member of the Scientific Advisory Board of Oncoholdings.

Oncoholdings specifically targets drug candidates for development with the potential to:

  • Demonstrate superiority over standard-of-care in pre-clinical or early human trials.
  • Address significant unmet medical needs in oncology.
  • Leverage Oncoholdings' significant expertise in cancer trial design and execution.

"Through our partnership with TGen Drug Development we are confident that we have secured a team comprised of the of the world's top scientists and researchers to develop Oncoholdings' drug portfolio," said Dr. Jeffrey Evans, founder and Chief Executive Officer of Oncoholdings.

"TD2's vast knowledge and experience developing cancer therapies is important to Oncoholdings, as we are positioned to advance more than a dozen compounds with various mechanisms of action. We are very pleased to have found a partner that can meet the challenges of rapidly and effectively progressing our strategy," said Dr. Evans, who also is the former co-founder and President of Rondaxe, a leading pharmaceutical consultancy.

Oncoholdings expects to announce the acquisition of its first group of products in the first quarter of 2011. Among these first products is a novel first-in-class therapy, as well as products with clearly superior efficacy and safety profiles relative to existing therapeutics. Those interested in discussing opportunities with Oncoholdings are encouraged to contact Dr. Evans at:


Contact: Steve Yozwiak
The Translational Genomics Research Institute

Related medicine news :

1. Michael J. Fox Foundation Awards $1 Million to Drive Critical New Research Tools and Technologies in Parkinsons Drug Development
2. Hayes Announces Appointment Of Dr Susan Levine To The Medicare Evidence Development and Coverage Advisory Committee (MEDCAC)
3. Flat Head Syndrome Linked to Developmental Delays
4. Pharmacokinetic/Pharmacodynamic Data Support Further Development of Tobiras Next-Generation CCR5 Receptor Antagonist
5. Chemical tags likely to affect metabolism, cancer development
6. The role of sleep in brain development
7. Talaris Advisors Attracts Veteran Team of Strategic Drug Development Managers
8. Antidepressants in Pregnancy May Delay Developmental Milestones
9. Secretary Clintons Approach to Development: Good Rhetoric, Little Action?
10. Sisters of Charity Health System Welcomes Mark Wiedt to its Business Development Team
11. Avoiding Dairy Due to Lactose Intolerance is Unnecessary in Most Cases and May Pose Diet and Health Risks, Concludes National Institutes of Health Consensus Development Conference Panel
Post Your Comments:
(Date:6/27/2016)... ... 2016 , ... TherapySites, the leading website and ... Tennessee Counseling Association. This new relationship allows TherapySites to continue to extend ... exclusive benefits and promotional offers. , "TCA is extremely excited about this new ...
(Date:6/26/2016)... ... 2016 , ... Quality metrics are proliferating in cancer care, and are derived ... eye of the beholder, according to experts who offered insights and commentary in the ... Care. For the full issue, click here . , For the American Society ...
(Date:6/26/2016)... NC (PRWEB) , ... June 26, 2016 , ... Brent Kasmer, a legally blind and ... to be personalized through a fitness app. The fitness app plans to fix the two ... currently only offer a one size fits all type program , They don’t ...
(Date:6/25/2016)... ... 2016 , ... The temporary closing of Bruton Memorial Library on June 21 due to a ... new, often overlooked aspect of head lice: the parasite’s ability to live away from a ... occurrence, but a necessary one in the event that lice have simply gotten out of ...
(Date:6/25/2016)... ... June 25, 2016 , ... Dr. ... from injury. Recently, he has implemented orthobiologic procedures as a method for treating ... one of the first doctors to perform the treatment. Orthobiologics are substances that ...
Breaking Medicine News(10 mins):
(Date:6/24/2016)... OAKLAND, N.J. , June 24, 2016 /PRNewswire/ ... in the design, development and manufacturing of collagen ... and regeneration announced today that Bill Messer ... Sales and Marketing to further leverage the growing ... surgery medical devices. Bill joins the ...
(Date:6/24/2016)... DUBLIN , June 24, 2016 ... and Markets has announced the addition of the ... their offering. ... products and provides an updated review, including its applications ... covering the total market, which includes three main industries: ...
(Date:6/24/2016)... June 24, 2016 Dehaier Medical Systems Ltd. ... which develops, markets and sells medical devices and wearable ... signed a strategic cooperation agreement with Hongyuan Supply Chain ... Chain") on June 20, 2016, to develop Dehaier,s new ... cooperation agreement, Dehaier will leverage Hongyuan Supply Chain,s sales ...
Breaking Medicine Technology: